- About us
- About Vaccines
- Media centre
- EU initiatives
Vaccines Europe launched a Manifesto calling for action of European policy makers to harness the 2017-2019 momentum on vaccination and protect European citizens against vaccine-preventable diseases
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
The World Health Organization (WHO) recommendations for the viruses to be included in influenza vaccines each season provide critical guidance to national public health authorities, regulatory agencies and vaccine manufacturers in advance of development and production.
During the 21st February 2019 meeting (Beijing, China), the WHO postponed the recommendation of the A (H3N2) strain candidate. One month later, on the 21st of March 2019, the WHO recommended the A(H3N2) vaccine strain for the Northern Hemisphere 2019-2020 season. This was an A/Kansas/14/2017 (H3N2)-like virus (see link for the WHO 2019-2020 strain recommendation).
In line with the published statement of the International Federation of Pharmaceutical Manufacturers & Associations, IFPMA (see link for the IFPMA statement), Vaccines Europe (VE) would also like to reiterate that protecting public health through annual seasonal influenza vaccination campaigns and achieving vaccination coverage goals are critical. Following the WHO’s recommendations, it takes approximately 6-8 months to produce and approve the full global supply of influenza vaccines. VE encourages National Health Authorities to continue preparing their influenza vaccination campaigns, mindful of potential changes to the campaign start and end dates, given the late WHO announcement on A/H2N3 strain candidate.
As a longstanding public health partner in the field, VE and its members are closely cooperating with European and National Regulatory Authorities to minimise any potential delays and provide a sustainable and timely supply of influenza vaccines for the 2019/20 season.
17 April 2019
The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon Europe legislation, including areas for partnerships and missions, which clearly demonstrates Europe’s commitment to research and innovation.
We welcome the overall structure and ambition of Horizon Europe. Europe has been at the forefront of life science research and a health mission is a palpable signal that it intends to keep on striving for excellence and impact. The challenges identified in the Horizon Europe “Health” cluster, with activities across the whole research and innovation spectrum, are centred on relevance and impact for patients and society. Read more…
6 March 2019 – Brussels, Belgium: Vaccines Europe launched a Manifesto today calling for action of European policy makers to harness the 2017-2019 momentum on vaccination and protect European citizens against vaccine-preventable diseases.
Access the manifesto here.
The manifesto outlines the three visions of the innovative vaccine industry in Europe:
Health for all, highlighting the importance of vaccination throughout the life-span and role of all healthcare professionals in informing their patients about the importance of vaccination as well as being vaccinated themselves;
European excellence, proving the innovative vaccine industry should stay in Europe and what role existing and new vaccines have to play in the fight against AMR; and
Stronger together, summarising the benefits of sustainable vaccine supply and demand ecosystem in Europe and the importance of e-health for national immunisation programmes.
The manifesto highlights the importance of cooperation of all stakeholders in addressing vaccine and vaccination issues in Europe. It lays out the asks of the European-based innovative vaccine industry, a stakeholder who has a role to play in the ongoing EU initiatives on vaccination.
UTRECHT and BILTHOVEN, Netherlands, Feb. 4, 2019 /PRNewswire/ — Recently, the EU-sponsored Vaccines andInfecTious diseases in the Ageing popuLation (VITAL) project was launched. VITAL will address – in a public-private consortium – the challenges of infections in the elderly and the potential of infection prevention by vaccination.
Within the VITAL project, which will run from 2019-2023, University Medical Center (UMC) Utrecht will be the managing entity and scientific lead. The € 12.4 million project is sponsored by the European Union’s Innovative Medicines Initiative(IMI) with a grant of € 5.5 million which will be matched by grants in total of € 6.9 million from the European Federation of Pharmaceutical Industries Associations (EFPIA). The consortium academic leader is prof. dr. Debbie van Baarle, professor of Immunology of Vaccinations at UMC Utrecht and Head of the Department of Immune Mechanisms at the Centre for Immunology of Infectious Diseases and Vaccines at the National Institute of Health and the Environment(RIVM) in the Netherlands.
See the full press release here.